XM无法为美国居民提供服务。

XM无法为美国居民提供服务。
V
V

Vertex

市场新闻

Reuters - 5天前

Why gene therapy for sickle cell is slow to catch on with patients

INSIGHT-Why gene therapy for sickle cell is slow to catch on with patients By Deena Beasley LOS ANGELES, Sept 28 (Reuters) - Student Zoe Davis, 20, was just weeks into her junior year when she landed back in the hospital with severe sickle cell pain earlier this month. She is doing what she can to prevent the crippling attacks in her arms, legs and abdomen that are becoming more frequent.
N
P
V
Reuters - 6天前

Pfizer's Oxbryta exit may hasten trials of rival experimental sickle cell drugs, analysts say

UPDATE 1-Pfizer's Oxbryta exit may hasten trials of rival experimental sickle cell drugs, analysts say EMA raises concerns about deaths in Oxbryta trials Shares of Agios and Fulcrum rise after Pfizer's decision Adds FDA statement in paragraph 4 By Kashish Tandon and Christy Santhosh Sept 26 (Reuters) - Pfizer's PFE.N decision late on Wednesday to withdraw its sickle cell disease treatment due to the risk of death could help speed up trials of new experimental rivals, Wall Street analysts said.
N
P
V
Reuters - 6天前

Pfizer's Oxbryta exit may hasten trials of rival experimental sickle cell drugs, analysts say

Pfizer's Oxbryta exit may hasten trials of rival experimental sickle cell drugs, analysts say EMA raises concerns about deaths in Oxbryta trials Shares of Agios and Fulcrum rise after Pfizer's decision By Kashish Tandon and Christy Santhosh Sept 26 (Reuters) - Pfizer's PFE.N decision late on Wednesday to withdraw its sickle cell disease treatment due to the risk of death could help speed up trials of new experimental rivals, Wall Street analysts said.
N
P
V
Reuters - 1周前

Health Canada Grants Marketing Authorization Of First Crispr/Cas9 Gene-Edited Therapy, Casgevy® (Exagamglogene Autotemcel), For The Treatment Of Sickle Cell Disease And Transfusion-Dependent Beta Thalassemia

BRIEF-Health Canada Grants Marketing Authorization Of First Crispr/Cas9 Gene-Edited Therapy, Casgevy® (Exagamglogene Autotemcel), For The Treatment Of Sickle Cell Disease And Transfusion-Dependent Beta Thalassemia Vertex Pharmaceuticals Inc VRTX.O : HEALTH CANADA GRANTS MARKETING AUTHORIZATION OF FIRST CRISPR/CAS9 GENE-EDITED THERAPY, CASGEVY® (E
V
Reuters - 1周前

Bluebird bio to cut 25% of jobs in fresh bid to battle cash crunch

UPDATE 2-Bluebird bio to cut 25% of jobs in fresh bid to battle cash crunch Adds CEO statement in paragraph 5, background throughout Sept 24 (Reuters) - Bluebird bio BLUE.O will lay off about 25% of its workforce, or 95 employees, the gene therapy maker said on Tuesday, in a second major restructuring in two years as the company focuses on launching its treatments amid a cash crunch.
V
Reuters - 4周前

Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT

BUZZ - Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT Nasdaq 100 .NDX Top Performers Percent Change Dollar Tree Inc DLTR.OQ +7.2% Tesla Inc TSLA.OQ +4.3% Zscaler Inc ZS.OQ +3.1% Comcast Corp CMCSA.OQ +2.7% Amazon.com Inc AMZN.OQ +2.3% Bottom Performers Percent Change Copart Inc CPRT.OQ -6.6% Old Dominion Freight Line Inc ODFL.OQ -5.4% AstraZeneca PLC AZN.OQ -3.4% Super Micro Computer Inc SMCI.OQ -3.1% Vertex Pharmaceuticals Inc VRTX.OQ -2.6% The Nasdaq 100 .NDX lost 36.77 points
A
A
C
T
V
D
U
C
O
Reuters - 4周前

Nasdaq top and bottom performing stocks at about 12:01 p.m. EDT

BUZZ - Nasdaq top and bottom performing stocks at about 12:01 p.m. EDT Nasdaq 100 .NDX Top Performers Percent Change Tesla Inc TSLA.OQ +3.2% Dollar Tree Inc DLTR.OQ +2.3% Amazon.com Inc AMZN.OQ +2.1% Comcast Corp CMCSA.OQ +1.6% Arm Holdings PLC ARM.OQ +1.2% Bottom Performers Percent Change Copart Inc CPRT.OQ -7.1% Old Dominion Freight Line Inc ODFL.OQ -6.8% AstraZeneca PLC AZN.OQ -3.5% Vertex Pharmaceuticals Inc VRTX.OQ -3.1% Regeneron Pharmaceuticals Inc REGN.OQ -3.0% The Nasdaq 100 .NDX lost 9
A
A
C
R
T
V
D
U
C
O
Reuters - 1个月前

Nasdaq top and bottom performing stocks at about 12:01 p.m. EDT

BUZZ - Nasdaq top and bottom performing stocks at about 12:01 p.m. EDT Nasdaq 100 .NDX Top Performers Percent Change Gilead Sciences Inc GILD.OQ +2.0% Vertex Pharmaceuticals Inc VRTX.OQ +1.8% Copart Inc CPRT.OQ +1.2% Verisk Analytics Inc VRSK.OQ +1.2% Old Dominion Freight Line Inc ODFL.OQ +1.1% Bottom Performers Percent Change Super Micro Computer Inc SMCI.OQ -25.1% PDD Holdings Inc PDD.OQ -6.3% Arm Holdings PLC ARM.OQ -5.5% Lululemon Athletica Inc LULU.OQ -4.4% Micron Technology Inc MU.OQ -4.3%
G
L
M
V
V
U
P
C
O
Reuters - 2个月前

Financial Times - Aug 8

PRESS DIGEST- Financial Times - Aug 8 Aug 8 (Reuters) - The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy. Headlines - NHS in England to roll out 1.7 mln pound Crispr gene editing drug - Ministry of Defence asks suppliers to identify budget cuts - H2O Asset Management to pay investors 250 mln euros after FCA finds 'serious breaches' - UK signals move to curb overseas hiring for tech and engineering jobs Overview
V
Reuters - 2个月前

British Business - August 8

PRESS DIGEST-British Business - August 8 Aug 8 (Reuters) - The following are the top stories on the business pages of British newspapers. Reuters has not verified these stories and does not vouch for their accuracy. The Times - Asset manager H2O has agreed to pay out 250 million euros ($273.35 million) to investors who have been trapped since 2020 in illiquid funds linked to Lars Windhorst, the German financier.
G
V
Reuters - 2个月前

UK's NHS to roll out Vertex/CRISPR gene therapy for rare blood disorder

UPDATE 1-UK's NHS to roll out Vertex/CRISPR gene therapy for rare blood disorder Updates with details from statement in paragraphs 2-6, updates with background in paragraphs 7-8 Aug 7 (Reuters) - Britain's National Health Service (NHS) will begin to roll out a gene therapy from Vertex Pharmaceuticals VRTX.O and CRISPR Therapeutics CRSP.BN to treat rare blood disorder beta thalassemia, Vertex said in a statement on Wednesday.
V
Reuters - 2个月前

UK's NHS to roll out Vertex/CRISPR gene therapy for rare blood disorder

UPDATE 1-UK's NHS to roll out Vertex/CRISPR gene therapy for rare blood disorder Updates with details from statement in paragraphs 2-6, updates with background in paragraphs 7-8 Aug 7 (Reuters) - Britain's National Health Service (NHS) will begin to roll out a gene therapy from Vertex Pharmaceuticals VRTX.O and CRISPR Therapeutics CRSP.BN to treat rare blood disorder beta thalassemia, Vertex said in a statement on Wednesday.
V
Reuters - 2个月前

UK's NHS to roll out Vertex/CRISPR gene therapy for rare blood disorder

UK's NHS to roll out Vertex/CRISPR gene therapy for rare blood disorder Aug 7 (Reuters) - Britain's National Health Service(NHS) will begin rolling out Vertex Pharmaceuticals VRTX.O and CRISPR Therapeutics' CRSP.BN gene therapy to treat rare blood disorder beta thalassemia, Vertex said in a statement on Wednesday. Reporting by Gursimran Kaur in Ben
V
Reuters - 2个月前

Vertex Announces Casgevy Reimbursement Agreement For Treatment Of Transfusion-Dependent Beta Thalassemia In England

BRIEF-Vertex Announces Casgevy Reimbursement Agreement For Treatment Of Transfusion-Dependent Beta Thalassemia In England Aug 7 (Reuters) - Vertex Pharmaceuticals Inc VRTX.O : VERTEX ANNOUNCES CASGEVY™ REIMBURSEMENT AGREEMENT FOR THE TREATMENT OF TRANSFUSION-DEPENDENT BETA THALASSEMIA IN ENGLAND VERTEX PHARMACEUTICALS - ELIGIBLE TRANSFUSION-DEPEN
V
Reuters - 2个月前

US FDA approves Novartis' kidney disease drug

UPDATE 2-US FDA approves Novartis' kidney disease drug Adds background in paragraphs 6 to 10 By Sriparna Roy Aug 7 (Reuters) - The U.S. Food and Drug Administration has approved the use of Novartis' NOVN.S drug to reduce excess protein in the urine of patients with a type of kidney disease, the health regulator's website showed on Wednesday. The drug, Fabhalta, is already approved to treat adults with paroxysmal nocturnal hemoglobinuria, a rare blood disorder.
N
V
Reuters - 2个月前

U.S. Booking Holdings, Doordash, Vertex Pharmaceuticals

U.S. RESEARCH ROUNDUP- Booking Holdings, Doordash, Vertex Pharmaceuticals Aug 5 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies including Booking Holdings, Doordash and Vertex Pharmaceuticals, on Monday. HIGHLIGHTS * Academy Sports and Outdoors Inc ASO.O : JP Morgan cuts to neutral from overweight * Booking Holdings Inc BKNG.O : Jefferies cuts target price to $4350 from $4650 * Doordash DASH.O : D.A.
A
B
C
C
C
C
E
V
E
A
B
C
C
C
C
Reuters - 2个月前

US Q2 earnings growth estimate dips, reflecting Vertex loss, LSEG says

UPDATE 1-US Q2 earnings growth estimate dips, reflecting Vertex loss, LSEG says Updates with details on Vertex Pharmaceuticals By Caroline Valetkevitch NEW YORK, Aug 2 (Reuters) - The earnings growth estimate for S&P 500 .SPX companies for the second quarter dipped to 12.9% as of Friday from 13.3% on Thursday, according to LSEG data. The latest estimate is based on actual results from 376 of the S&P 500 companies and estimates for the rest.
V
U
Reuters - 2个月前

Vertex Pharma raises annual revenue forecast on strong demand for its cystic fibrosis treatments

Vertex Pharma raises annual revenue forecast on strong demand for its cystic fibrosis treatments Aug 1 (Reuters) - Vertex Pharmaceuticals VRTX.O raised its annual revenue forecast on Thursday, betting on robust demand for its cystic fibrosis (CF) treatments. The drugmaker now expects 2024 product revenue in the range of $10.65 to $10.85 billion, compared to its prior forecast of $10.55 to $10.75 billion.
V
Reuters - 2个月前

Vertex Pharmaceuticals Q2 Net Income 3,593.6 Million

BRIEF-Vertex Pharmaceuticals Q2 Net Income USD -3,593.6 Million Aug 01 (Reuters) - Vertex Pharmaceuticals Q2 revenue USD 2,645.6 million vs. IBES estimate USD 2,662 million. Q2 adjusted operating income USD -3,514.7 million vs. IBES estimate USD 1,243 million Q2 pretax profit USD -3,391.2 million vs. IBES estimate USD 1,345 million Q2 adjusted net income USD -3,593.6 million vs.
V
Reuters - 2个月前

Nasdaq top and bottom performing stocks at about 12:01 p.m. EDT

BUZZ - Nasdaq top and bottom performing stocks at about 12:01 p.m. EDT Nasdaq 100 .NDX Top Performers Percent Change Meta Platforms Inc META.OQ +6.1% Dexcom Inc DXCM.OQ +3.5% Cognizant Technology Solutions Corp CTSH.OQ +2.8% Vertex Pharmaceuticals Inc VRTX.OQ +1.8% AstraZeneca PLC AZN.OQ +1.4% Bottom Performers Percent Change Moderna Inc MRNA.OQ -19.5% Arm Holdings PLC ARM.OQ -16.0% Qualcomm Inc QCOM.OQ -8.7% Lam Research Corp LRCX.OQ -8.3% Micron Technology Inc MU.OQ -6.7% The Nasdaq 100 .NDX l
A
C
M
Q
V
L
U
D

商品详情

热门商品

免责声明: XM Group仅提供在线交易平台的执行服务和访问权限，并允许个人查看和/或使用网站或网站所提供的内容，但无意进行任何更改或扩展，也不会更改或扩展其服务和访问权限。所有访问和使用权限，将受下列条款与条例约束：(i) 条款与条例；(ii) 风险提示；以及(iii) 完整免责声明。请注意，网站所提供的所有讯息，仅限一般资讯用途。此外，XM所有在线交易平台的内容并不构成，也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。

所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。

本网站上由XM和第三方供应商所提供的所有内容，包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接，皆保持不变，并作为一般市场评论所提供，而非投资性建议。所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为适用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解，XM非独立投资研究提示和风险提示相关资讯，更多详情请点击 这里。

风险提示： 您的资金存在风险。杠杆商品并不适合所有客户。请详细阅读我们的风险声明。